Our vision for the oncology-focused IL-2-based CUE-100 series is centered on three key pillars; validation, expansion, and acceleration of our pipeline assets. We believe our lead clinical candidate, CUE-101, validates our technology platform and effectively reduces the risk profile of our IL-2-based pipeline, since the core framework is conserved.
Learn more about CUE-101.
CUE-102 and CUE-103 allow us to expand our pipeline by incorporating different tumor antigens and human leukocyte antigen, or HLA, alleles, exploiting the modularity of this platform.
Neo-STAT™ and RDI-STAT™ allow us to address the key challenges of tumor heterogeneity and tumor escape mechanisms. Based upon early, emerging clinical data from CUE-101, we are planning to focus our resources and core competencies on the further development of CUE-101 and additional CUE-100 series candidates, such as CUE-102 and CUE-103.
Cue Biopharma welcomes your interest in partnering opportunities for our oncology programs.
For inquiries, please contact us at BD@cuebio.com.
Current Industry Collaborations in Oncology
Cue Biopharma entered into a strategic collaboration with LG Chem Life Sciences, the life sciences division of LG Chem Ltd. in November 2018. Under the collaboration, LGC has an exclusive right to develop and commercialize CUE-101 and CUE-102 for Asia, while Cue Biopharma retains the right to develop and commercialize CUE-101, CUE-102 and CUE-103 for the United States and all other countries outside of Asia.
Cue Biopharma entered into a clinical trial collaboration agreement with Merck and Co., Inc., in April 2020, to evaluate CUE-101 in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment for HPV16+ recurrent/metastatic head and neck cancer. Under the terms of the agreement, Cue Biopharma is conducting the Phase 1 study, designated KEYNOTE-A78 in parallel with Cue Biopharma’s ongoing Phase 1 monotherapy study of CUE-101 for second line and beyond therapy for the same patient population.
